Depressive symptoms in schizophrenia, while highly prevalent, often chronic, and disabling, remain relatively understudied. Antidepressants are commonly used in clinical practice to treat a variety of symptoms in patients with schizophrenia. Although some literature describes the treatment of syndromal depression in primarily young adults with schizophrenia, comparatively little research is available to guide the treatment of subsyndromal depressive symptoms in this population, especially in middle-aged and older adults with schizophrenia. Older people with schizophrenia differ from their younger counterparts in several important ways, such as having greater physical comorbidity, cognitive impairment, and a higher risk of side effects. This study will evaluate the efficacy and safety of antidepressant (citalopram) versus placebo augmentation of atypical antipsychotics to treat subsyndromal, residual depressive symptoms in middle-aged and older patients with schizophrenia. This collaborative, two-site (University of California, San Diego and University of Cincinnati), five-year study hypothesizes that citalopram augmentation of antipsychotic medication will be more effective than augmentation with placebo at reducing depressive symptoms and enhancing functioning and quality of life. We propose to enroll a total of 240 outpatients with schizophrenia, who are 55 years or older and have a Hamilton Depression Rating Scale 17-item score of ten or greater, into a randomized, double-blind, flexible-dose, placebo-controlled study. After stabilization for at least four weeks on an atypical antipsychotic agent (either risperidone or olanzapine), patients who have residual depressive symptoms (HAM-D score of ten or greater) will be randomized to one of the following interventions: atypical antipsychotic (risperidone or olanzapine) plus citalopram; or atypical antipsychotic (risperidone or olanzapine) plus placebo. The double-blind treatment period will be three months with a follow-up assessment three months later. Depressive symptoms and side effects will be assessed weekly for the first month, biweekly for the second month, and again at the end of the third month. In addition, we will evaluate cognitive, motor and daily functioning, quality of life, and medication adherence throughout the study. Unique to this proposal, we will use performance-based outcome measures to assess real-world functional capacities. By providing empirical evidence to guide treatment of depressive symptoms in patients with schizophrenia, the study could have significant public health implications for the reduction of disability and the enhancement of quality of life in this patient population.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH063931-04
Application #
6793297
Study Section
Special Emphasis Panel (ZMH1-CRB-X (01))
Program Officer
Evans, Jovier D
Project Start
2001-09-01
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
4
Fiscal Year
2004
Total Cost
$315,000
Indirect Cost
Name
Veterans Medical Research Fdn/San Diego
Department
Type
DUNS #
933863508
City
San Diego
State
CA
Country
United States
Zip Code
92161
Hall, Charles A; Reynolds 3rd, Charles F; Butters, Meryl et al. (2014) Cognitive functioning in complicated grief. J Psychiatr Res 58:20-5
Dawes, Sharron E; Palmer, Barton W; Meeks, Thomas et al. (2012) Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression? Neuropsychobiology 65:168-72
Kasckow, John; Felmet, Kandi; Zisook, Sidney (2011) Managing suicide risk in patients with schizophrenia. CNS Drugs 25:129-43
Felmet, Kandi; Zisook, Sidney; Kasckow, John W (2011) Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin Schizophr Relat Psychoses 4:239-50
Kasckow, John; Lanouette, Nicole; Patterson, Thomas et al. (2010) Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning. Int J Geriatr Psychiatry 25:183-90
Zisook, Sidney; Kasckow, John W; Lanouette, Nicole M et al. (2010) Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J Clin Psychiatry 71:915-22
Kasckow, John; Fellows, Ian; Golshan, Shahrokh et al. (2010) Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response. Am J Geriatr Psychiatry 18:853-7
Nyer, Maren; Kasckow, John; Fellows, Ian et al. (2010) The relationship of marital status and clinical characteristics in middle-aged and older patients with schizophrenia and depressive symptoms. Ann Clin Psychiatry 22:172-9
Zisook, Sidney; Kasckow, John W; Golshan, Shahrokh et al. (2009) Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry 70:562-71
Roseman, Ashley S; Kasckow, John; Fellows, Ian et al. (2008) Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia. Int J Geriatr Psychiatry 23:760-5

Showing the most recent 10 out of 15 publications